SLC5A2 and type 2 diabetes mellitus: Accumulating evidence from experimental and clinical studies supports the antioxidant roles of SGLT2 inhibitors in T2DM, with mechanisms that involve both inhibition of free radical generation and regulation of antioxidant systems via direct modulative properties, as well as indirect influences from glucose-lowering and hemodynamic effects.